RHA 2, RHA 3, RHA 4 dermal fillers
FDA premarket approval P170002/S009 · decided 2020-03-10
Approval details
- PMA number
- P170002
- Supplement
- S009
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- RHA 2, RHA 3, RHA 4 dermal fillers
- Generic name
- Implant, dermal, for aesthetic use
- Applicant
- Teoxane S.A.
- Date received
- 2020-02-14
- Decision date
- 2020-03-10
- Days to decision
- 25 days
- Decision code
- OK30
- Product code
- LMH
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Geneva
- Statement
- Addition of an alternative supplier of the reference standard lidocaine hydrochloride monohydrate used for the lidocaine assay for RHA 2, RHA 3, and RHA 4.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.